Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) Share Price

Company Profile

Business description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
Contact
No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park
Wenjiang
Sichuan
Chengdu
CHN
T: +86 4006887002
https://www.kelun-biotech.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,045

Recommended

Microsoft’s earnings report is expected to touch on AI adoption and monetization.

Dan Romanoff, CPA | 23 April 2026

The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.

Jon Mills, CFA | 23 April 2026

How investors can uncover value beyond the index heavyweights.

Tyger Fitzpatrick | 23 April 2026

Index	Last price	Change	% Change
All Ordinaries	9,024.20	27.20	-0.30%
CAC 40	8,181.27	24.84	0.30%
DAX 40	24,085.66	109.24	-0.45%
Dow JONES (US)	49,490.03	340.65	0.69%
FTSE 100	10,405.42	71.04	-0.68%
HKSE	25,915.20	248.04	-0.95%
NASDAQ	24,657.57	397.60	1.64%
Nikkei 225	59,140.23	445.63	-0.75%
NZX 50 Index	12,884.93	60.67	-0.47%
S&P 500	7,137.90	73.89	1.05%
S&P/ASX 200	8,793.40	26.10	-0.30%
SSE Composite Index	4,093.25	13.01	-0.32%